Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21222793 | 1.00 | IGF1R (0.36) | IGF1RTRPV1MEN1KMT2APDE3B | |
| SCHEMBL21234153 | 0.88 | PDE3B (0.34) | PDE3BACVR1 | |
| SCHEMBL21233809 | 0.88 | ACVR1 (0.31) | MEN1KMT2AEPHX2SMN1; SMN2P2RX7 | |
| SCHEMBL21234032 | 0.86 | EPHX2 (0.35) | PDE3BEPHX2ALDH1A1SMN1; SMN2MALT1 | |
| SCHEMBL21234034 | 0.85 | ACVR1 (0.34) | MEN1KMT2APDE3BCYP3A4MAPT | |
| SCHEMBL21225886 | 0.85 | ACVR1 (0.34) | MEN1KMT2APDE3BCYP3A4MAPT | |
| SCHEMBL21222803 | 0.84 | ROCK2 (0.47) | — | |
| SCHEMBL21225908 | 0.84 | ROCK2 (0.47) | — | |
| SCHEMBL28560454 | 0.83 | TRPV1 (0.34) | IGF1RTRPV1MEN1KMT2AEPHX2 | |
| SCHEMBL21222832 | 0.82 | POLB (0.37) | MEN1KMT2AALDH1A1KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3746079-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS | Bayer Aktiengesellschaft (DE) | 2020-12-09 | — | — | EP | disclosed |
| CN-112040951-A | Antibody Drug Conjugates (ADC) with NAMPT inhibitors | 拜耳股份公司 | 2020-12-04 | — | — | CN | disclosed |
| US-20200360531-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-19 | — | — | US | disclosed |
| WO-2019149637-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360531-A1 | ANTIBODY DRUG CONJUGATES (ADCS) WITH NAMPT INHIBITORS | NAMPT, B3GNT2, NQO1 | IGF1R 1993/4885TRPV1 4432/4885MEN1 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.